Who will be ahead in medical research? U.S. or China

Every Minute, 4 People Die of Cancer in China
May 8, 2018
Each Year, 20 Million New Babies in China Call for Stem Cell Therapy
May 21, 2018

Who will be ahead in medical research? U.S. or China

Grace Palma, CEO of China Med Device

On my flight to China, my seat mate is a Harvard Medical School professor specializing in stem cell research.  We were talking about differences of research in the US and China. We mutually agreed to the following:

  1. Chinese government has given research labs resources, poising them to do great science. NIH grant funding in the US is shrinking, although this year there was a significant increase in NIH budget.
  2. Research labs in China have resources to purchase the latest and best equipment. Government provides labs with the latest equipment.  On the other hand, research labs in the U.S. must buy their own equipment with their research grants. Research labs even at leading institutions like Harvard have equipment from 10 years ago or use of new equipment through core facilities can be expensive to utilize.
  3. Chinese post docs or researchers are excellent dedicated workers. They are good at execution and follow directions well.  They are still working on independent thinking and initiatives.
  4. Post docs in general sometimes believe they are better than their teachers. US and European postdocs though tend to be better trained to be creative and adventurous.

These comments may be a little stereotypical but there is truth based on my 20+ years of medical device commercial experience between the U.S. and China. With the global education and research exchanges, China will be ahead in 10 years or so to bring these research results to commercial success. It could be shorter but other factors such as regulatory approval, preclinical and clinical. This is my gut guess.

 

About China Med Device, LLC

China Med Device, LLC provides turn-key solutions for western medical device/IVD companies to enter China with regulation and commercialization services. Our CFDA regulatory services cover strategy, premarket submission, clinical evaluation, CRO, post market compliance as well as legal agent representation. Our commercial services cover market assessment research, reimbursement, partnership, distribution qualification and management. We have an office in Beijing, Suzhou and Boston. Our management team have 100+ years of combined experience in medical device and IVD and had been involved with 1,000+ CFDA certificates, 200+ companies’ success.